解毒活血方对经皮冠状动脉介入术患者围术期心肌损伤的影响
|
摘要
目的观察解毒活血配方颗粒冲服对经皮冠状动脉介入术(PCI)患者的围术期心肌损伤的影响。方法 160例接受PCI术的心绞痛患者随机分为解毒活血组(n=84)和对照组(n=76),解毒活血组给予常规治疗同时术前第7天给予解毒活血配方颗粒冲服,每日1剂。对照组给予基础药物治疗。测定PCI术前及术后12 h、24 h的血清肌酸激酶同工酶(CK-MB)和肌钙蛋白I(cTn I)浓度。结果解毒活血组PCI术后12 h、24 h cTn I和CK-MB水平均显著低于对照组(P=0.0038,P=0.027 6;P=0.001 2,P=0.002 7)。解毒活血组患者术后cTn I和CK-MB升高大于正常值3倍者构成比均显著低于对照组(P=0.008 2,P=0.007 6)。结论术前给予解毒活血配方颗粒对于PCI围手术期病人的心肌损伤具有一定的保护作用。
Objective To observe the influence of Jiedu Huoxue Fang( Detoxification and BloodActivating Granules) on perioperative myocardial injury in patients undergone percutaneous coronary intervention( PCI). Methods The patients with angina pectoris received PCI( n = 160) were randomly divided into Jiedu Huoxue Fang group( n = 84) and control group( n = 76). The Jiedu Huoxue Fang group was given routine treatment and Jiedu Huoxue Fang( 1 dose/d) 7 d before PCI. The control group was treated with basic drugs. The levels of serum creatine kinase-M B isoenzyme( CK-MB) and cardiac troponin I( cTn I) were detected before and 12 h and 24 h after PCI. Results The levels of serum cTn I and CK-MB were significantly lower in Jiedu Huoxue Fang group than those in control group 12 h after PCI( P = 0. 003 8,P = 0. 027 6) and 24 h after PCI( P = 0. 001 2,P = 0. 002 7). The constituent ratio of patients with cTn I and CK-MB increasing by 3 times more than normal value was significantly lower in Jiedu Huoxue Fang group than that in control group( P = 0. 008 2,P = 0. 007 6). Conclusion Jiedu Huoxue Fang administrated before PCI has a certain preventive effect on perioperative myocardial damage.
Objective To observe the influence of Jiedu Huoxue Fang( Detoxification and BloodActivating Granules) on perioperative myocardial injury in patients undergone percutaneous coronary intervention( PCI). Methods The patients with angina pectoris received PCI( n = 160) were randomly divided into Jiedu Huoxue Fang group( n = 84) and control group( n = 76). The Jiedu Huoxue Fang group was given routine treatment and Jiedu Huoxue Fang( 1 dose/d) 7 d before PCI. The control group was treated with basic drugs. The levels of serum creatine kinase-M B isoenzyme( CK-MB) and cardiac troponin I( cTn I) were detected before and 12 h and 24 h after PCI. Results The levels of serum cTn I and CK-MB were significantly lower in Jiedu Huoxue Fang group than those in control group 12 h after PCI( P = 0. 003 8,P = 0. 027 6) and 24 h after PCI( P = 0. 001 2,P = 0. 002 7). The constituent ratio of patients with cTn I and CK-MB increasing by 3 times more than normal value was significantly lower in Jiedu Huoxue Fang group than that in control group( P = 0. 008 2,P = 0. 007 6). Conclusion Jiedu Huoxue Fang administrated before PCI has a certain preventive effect on perioperative myocardial damage.
引文
[1]HERRMANN J.Peri-procedural myocardial injury:2005update[J].Eur Heart J,2005,26(23):2493-2519.
[2]BRENER SJ,ELLIS SG,SCHNEIDER J,et al.Frequency and long-term impact of myonecrosis after coronary stenting[J].Eur Heart J,2002,23(11):869-876.
[3]SMITH SC,FELDMAN TE,HIRSHFELD JW,et al.ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention)[J].Circulation,2006,113(7):e166-286.
[4]王新东.冠心病伏毒损脉病机理论与应用浅析[J].南京中医药大学学报,2015,31(1):8-12.WANG XD.Application of the theory of potential toxin damaging the meridians of coronary heart disease[J].J Nanjing Univ Chin Med,2015,31(1):8-12.
[5]王新东,张苏洁,吴慧,等.基于“伏毒损脉”理论解毒活血配方颗粒治疗糖尿病相关性心绞痛[J].吉林中医药,2016,36(3):244-248.WANG XD,ZHANG SJ,WU H,et al.Jiedu Huoxue formula particles treating diabetes-associated angina based on“Fudu Sunmai”[J].Jilin Journal of Traditional Chinese Medicine,2016,36(3):244-248.
[6]马霞.金银花药理研究进展[J].医药前沿,2015,33(5):12-13.MA X.Progress in pharmacological research of honeysuckle[J].Journal of Frontiers of Medicine,2015,33(5):12-13.
[7]GAO S,LIU Z,LI H,et al.Cardiovascular actions and therapeutic potential of tanshinone IIA[J].Atherosclerosis,2012,220(1):3-10.
[8]陈云华,龚幕辛,卢旭然,等.鬼箭羽及同属植物主要药理作用及有效成分研究进展[J].北京中医药,2010,29(2):143-147.CHEN YH,GONG MX,LU XR,et al.Research progress on main pharmacological effects and active ingredients of Guijianyu(Euonymus alatus)[J].Beijing Journal of Traditional Chinese Medicine,2010,29(2):143-147.
[9]尹国平,张清哲,安月伟,等.温郁金化学成分及药理活性研究进展[J].中国中药杂志,2012,37(22):3354-3360.YIN GP,ZHANG QZ,AN YW,et al.Advance in chemical constituents and pharmacological activity of Curcuma wenyujin[J].China Journal of Chinese Materia Medica,2012,37(22):3354-3360.
[10]樊慧婷,丁世兰,林洪生.中药虎杖的药理研究进展[J].中国中药杂志,2013,38(15):2545-2548.FAN HT,DING SL,LIN HS.Pharmacological of Polygoni Cuspidati Rhizoma[J].China Journal of Chinese Materia Medica,2013,38(15):2545-2548.
[11]LIU J,WANG Y,QIU L,et al.Saponins of Panax notoginseng:chemistry,cellular targets and therapeutic opportunities in cardiovascular diseases[J].Expert Opin Investig Drugs,2014,23(4):523-539.
[12]郭晓庆,孙佳明,张辉.水蛭的化学成分与药理作用[J].吉林中医药,2015,35(1):47-50.GUO XQ,SUN JM,ZHANG H.Review of pharmacological effects and chemical compounds of leech[J].Jilin Journal of Traditional Chinese Medicine,2015,35(1):47-50.
[2]BRENER SJ,ELLIS SG,SCHNEIDER J,et al.Frequency and long-term impact of myonecrosis after coronary stenting[J].Eur Heart J,2002,23(11):869-876.
[3]SMITH SC,FELDMAN TE,HIRSHFELD JW,et al.ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention)[J].Circulation,2006,113(7):e166-286.
[4]王新东.冠心病伏毒损脉病机理论与应用浅析[J].南京中医药大学学报,2015,31(1):8-12.WANG XD.Application of the theory of potential toxin damaging the meridians of coronary heart disease[J].J Nanjing Univ Chin Med,2015,31(1):8-12.
[5]王新东,张苏洁,吴慧,等.基于“伏毒损脉”理论解毒活血配方颗粒治疗糖尿病相关性心绞痛[J].吉林中医药,2016,36(3):244-248.WANG XD,ZHANG SJ,WU H,et al.Jiedu Huoxue formula particles treating diabetes-associated angina based on“Fudu Sunmai”[J].Jilin Journal of Traditional Chinese Medicine,2016,36(3):244-248.
[6]马霞.金银花药理研究进展[J].医药前沿,2015,33(5):12-13.MA X.Progress in pharmacological research of honeysuckle[J].Journal of Frontiers of Medicine,2015,33(5):12-13.
[7]GAO S,LIU Z,LI H,et al.Cardiovascular actions and therapeutic potential of tanshinone IIA[J].Atherosclerosis,2012,220(1):3-10.
[8]陈云华,龚幕辛,卢旭然,等.鬼箭羽及同属植物主要药理作用及有效成分研究进展[J].北京中医药,2010,29(2):143-147.CHEN YH,GONG MX,LU XR,et al.Research progress on main pharmacological effects and active ingredients of Guijianyu(Euonymus alatus)[J].Beijing Journal of Traditional Chinese Medicine,2010,29(2):143-147.
[9]尹国平,张清哲,安月伟,等.温郁金化学成分及药理活性研究进展[J].中国中药杂志,2012,37(22):3354-3360.YIN GP,ZHANG QZ,AN YW,et al.Advance in chemical constituents and pharmacological activity of Curcuma wenyujin[J].China Journal of Chinese Materia Medica,2012,37(22):3354-3360.
[10]樊慧婷,丁世兰,林洪生.中药虎杖的药理研究进展[J].中国中药杂志,2013,38(15):2545-2548.FAN HT,DING SL,LIN HS.Pharmacological of Polygoni Cuspidati Rhizoma[J].China Journal of Chinese Materia Medica,2013,38(15):2545-2548.
[11]LIU J,WANG Y,QIU L,et al.Saponins of Panax notoginseng:chemistry,cellular targets and therapeutic opportunities in cardiovascular diseases[J].Expert Opin Investig Drugs,2014,23(4):523-539.
[12]郭晓庆,孙佳明,张辉.水蛭的化学成分与药理作用[J].吉林中医药,2015,35(1):47-50.GUO XQ,SUN JM,ZHANG H.Review of pharmacological effects and chemical compounds of leech[J].Jilin Journal of Traditional Chinese Medicine,2015,35(1):47-50.